Northrop Grumman (NOC) Q3 2026 Earnings Call Transcript

Northrop Grumman reported Q3 2026 sales of $11.1 billion, up 7%, diluted EPS of $7.89, up 3%, and record backlog of $110 billion, up 20%, with a 1.5x quarterly book-to-bill ratio. The company raised 2026 EPS guidance to $29.35–$29.75 and segment operating income guidance to $4.94–$5.04 billion; 2027 sales growth is projected at 5%–7%, with adjusted free cash flow of $3.3–$3.7 billion. Management cited strong program execution and defense demand, while warning that development-program discoveries and the timing of congressional appropriations could affect margins and growth.

Analysis

The bullish signal is revenue visibility, not yet proof of durable incremental returns. Backlog converts only as appropriations, contract awards, materials, and factory throughput align; a continuing resolution or supplier bottlenecks could defer growth without immediately impairing the headline backlog. More importantly, the mix shift toward B-21 and Sentinel raises the near-term share of technically complex work, so reported growth can coexist with margin volatility and fixed-price cost risk. The company itself flags development discoveries and B-21 mix as pressure points; successful test milestones reduce, but do not eliminate, that tail risk.

Cash quality deserves a discount: quarterly free cash flow benefited from a one-off asset sale and working-capital timing, while the capacity build requires substantial investment. Tax optimization can support cash for several years, but should not be capitalized as recurring operating improvement. The market may be over-reading backlog as an earnings annuity and underweighting the execution and funding gates between award and profitable production.

Over the next 1–3 months, watch the next guidance update, appropriations timing, production throughput, and any contract-cost revisions. Over 6–18 months, the key test is whether higher production volumes translate into margin and cash expansion after capex, particularly in Aeronautics. Microelectronics and quantum strategic alternatives add optionality, but are not yet underwritable earnings catalysts.

Key Decisions for Investors

• Avoid chasing NOC solely on backlog or the guidance increase. Consider building a long on market weakness only if subsequent updates sustain the growth outlook and show operating performance—not tax benefits or working-capital releases—driving earnings and cash.
• Treat B-21 execution as the principal thesis risk: monitor test milestones, fixed-price contract cost adjustments, and Aeronautics margin as the program becomes a larger sales mix. A material adverse cost revision or deterioration in test progress would invalidate the constructive view.
• Use appropriations and award timing as a 1–3 month catalyst watch. A prolonged continuing resolution or delayed awards would weaken the near-term growth case; verify whether orders are funded and moving into production rather than relying on backlog totals alone.
• Do not assign material value yet to the microelectronics or quantum review. Reassess only after NOC discloses a structure, funding requirements, and evidence of customer demand; a separation or outside investment could unlock value, but could also require capital or dilute control.